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OBJECTIVES: Chronic paracoccidioidomycosis can diffusely affect the lungs. Even after antifungal therapy,
patients may present with residual respiratory abnormalities due to fungus-induced lung fibrosis.
METHODS: A cross-sectional analysis of 50 consecutive inactive, chronic paracoccidioidomycosis patients was
performed using high resolution computed tomography, pulmonary function tests, ergospirometry, the six-
minute walk test and health-related quality of life questionnaires.
RESULTS: Radiological abnormalities were present in 98% of cases, the most frequent of which were
architectural distortion (90%), reticulate and septal thickening (88%), centrilobular and paraseptal emphysema
(84%) and parenchymal bands (74%). Patients typically presented with a mild obstructive disorder and a mild
reduction in diffusion capacity with preserved exercise capacity, including VO2max and six-minute walking
distance. Patient evaluation with the Saint-George Respiratory Questionnaire showed low impairment in the
health-related quality of life, and the Medical Research Council questionnaire indicated a low dyspnea index.
There were, however, patients with significant oxygen desaturation upon exercise that was associated with
respiratory distress compared with the non-desaturated patients. The initial counterimmunoelectrophoresis of
these patients was higher and lung emphysema was more prominent; however, there were no differences in
the interstitial fibrotic tomographic abnormalities, tobacco exposure, functional responses, exercise capacity or
quality of life.
CONCLUSIONS: Inactive, chronic paracoccidioidomycosis patients show persistent and disseminated radiological
abnormalities by high resolution computed tomography, short impairments in pulmonary function and low
impacts on aerobic capacity and quality of life. However, there was a subset of individuals whose functional
impairment was more severe. These patients present with higher initial serology and more severe emphysema,
stressing the importance of adequate treatment associated with tobacco exposure cessation.
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& INTRODUCTION
In 1908, Adolph Lutz first described the human
Paracoccidioides brasiliensis infection (1). This thermally
dimorphic fungus is acquired by inhalation of the infective
forms of the organism and causes notable, systemic mycosis
(2-4). The disease, termed paracoccidioidomycosis (PCM), is
the most common systemic mycosis affecting non-immuno-
compromised hosts in South America and Brazil, which
account for more than 80% of all reported cases (5-8).
Additionally, cases outside these areas continue to be
reported and are generally associated with long periods of
latency, representing endogenous reactivation of the infec-
tious focus that was previously acquired in endemic regions
(4). PCM is subdivided into the following two groups that
are differentiated by their time course and the age of the
host: juvenile and chronic forms. The juvenile form has an
acute or subacute clinical course with a predominantly
lymphatic distribution. The chronic or reactivation form has
a more insidious course in which the lung is the most
frequently involved organ, with lesser involvement of the
reticuloendothelial and lymphatic systems (3,4,9). The cure
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rate is high when adequate treatment is readily adminis-
tered, and mycological eradication can be achieved with
sulfonamides, azole compounds or amphotericin (9-11).
However, in pulmonary parenchyma, even after treatment,
P. brasiliensis induces chronic damage that leads to the
development of lung fibrosis, which is most likely due to
persistent antigenic stimulus that elicits a continuous
inflammatory response (12). This process can result in a
severe restriction of respiratory function and a decline in
work capacity, thereby affecting patient quality of life
(4,13,14). In fact, in more than 50% of cases in which the
patient receives an adequate course of therapy, pulmonary
fibrosis is radiographically documented at the end of the
treatment period (15). However, the true incidence and
severity of radiographical and functional disability of the
patient following treatment for this endemic mycosis
remain unknown.
The objective of this study was to characterize both the
residual pulmonary involvement in PCM by high resolution
computed tomography (HRCT) and the sequelae related to
lung function, exercise capacity and quality of life in the
inactive chronic form of PCM.
& PATIENTS AND METHODS
From July 2008 to July 2010, all PCM patients seen in the
outpatient clinic of the Pulmonary and Infectious Diseases
Divisions of the Hospital das Clinicas at the University of
Sao Paulo were invited to participate in the study. The
patients were included if the PCM diagnosis was confirmed
by the identification of P. brasiliensis yeast cells in biopsies
and/or other clinical specimens and/or serological diag-
nosis. The patients were enrolled if they met the criteria for
inactive disease as determined by a treatment length of at
least 6 months, negative mycological examinations, resolu-
tion of skin and mucosal lesions, low anti-P. brasiliensis
antibody titers by counterimmunoelectrophoresis (CIE)
(titers ,1:4 or a fall in at least four dilutions) and a lack of
radiological activity on chest radiographs (9,16,17). The
exclusion criteria were pulmonary co-infections, such as
tuberculosis, histoplasmosis or other chronic infections, or
lung neoplasia. From a cohort of 81 PCM patients, 72 met
the inclusion criteria, and 22 were excluded. Of the 22
excluded patients, 10 had the juvenile form, seven had
tuberculosis co-infections, three were tracheotomized, one
had microstomia and one refused. Of the 50 patients
included in the study, 47 were men ranging in age from
35 to 78 years, with a mean age of 56.9 years. All were
previously diagnosed based on mycological examination,
including direct visualization and/or culture of smears of
lesions and/or biopsies.
HRCT scans were obtained using 1 or 2 mm collimation
at 10 mm intervals (Multislice Philips Brilliance CT40,
Cleveland, United States). Two investigators (CF and
CRRC) blinded to the clinical history of the patients
retrospectively read the CT scans, and when necessary,
final decisions were reached by consensus. The findings
were analyzed with regard to distribution in the lung
parenchyma, (central, peripheral or both) and upper (above
the level of the tracheal carina), middle (between the level of
the carina and inferior pulmonary veins) and lower zones
(below the level of the inferior pulmonary veins) or a
combination of zones (2,18).
For the pulmonary function tests (PFT), all measurements
were obtained using the recommended standards (19-22).
Spirometry was performed using a calibrated pneumotacho-
graph (Medical Graphics Corporation, MGC, St. Paul, MN,
USA, 2005), whereas lung volumes and CO diffusing capacity
(DLCO) were obtained with a body plethysmograph (Elite Dx,
Elite SeriesTM, MGC). The following variables were considered:
FVC (forced vital capacity), FEV1 (expiratory forced volume in
the first second), IC (inspiratory capacity), TLC (total lung
capacity), RV (residual volume), MVV (maximal voluntary
ventilation) and DLCO. The predicted values were derived
based on the Brazilian population (19-21). For the cardiopul-
monary exercise test (CPET), a ramp symptom-limited CPET
was performed on a cycle (Corival, Lode B.V. Medical
Technology, Groningen, The Netherlands) consisting of a
2 min period of rest and 2 min period of warm-up, followed
by an incremental work-rate period, which was increased from
10 to 20 W/min. Oxygen saturation (SpO2) by pulse oximetry
(NONIN-ONYX, model 9500, Plymouth, MN, USA) and
electrocardiography (Welch Allyn CardioPerfect, Inc, NY) were
monitored continuously (23). The following variables were
recorded (CardiO2 System, MGC): work rate, VO2, minute-
ventilation (VE), carbon dioxide output (VCO2), tidal volume
(VT), respiratory rate (RR), respiratory exchange rate (RER) and
heart rate (HR). The predicted values for CPET were calculated
based on the Brazilian population (23). The six-minute walk test
(6MWT) was performed according to the ATS guidelines (24),
and the parameters analyzed were the distance walked
(meters), SpO2 minimum maintained for at least 10 seconds
and the difference between the basal saturation (at rest) and
minimal saturation achieved during the test (SpO2 basal – SpO2
min). The distance was analyzed based on the predictive
equations for the adult Brazilian population (25).
A standard questionnaire was administered by a pulmo-
nologist to obtain information on age, sex, body mass index,
smoking habits and possible respiratory co-infections. Two
specific respiratory questionnaires, the Saint George
Respiratory Questionnaire (SGRQ) (26,27), and Medical
Research Council (MRC) Dyspnea Questionnaire (28,29)
were used. The SGRQ is a standardized airway disease-
specific questionnaire divided into three subscales: symp-
toms, activity and impacts. The scores were calculated using
algorithms as recommended (P.W. Jones, St George’s
Hospital Medical School, London, UK, personal commu-
nication). For each subscale and the overall questionnaire,
scores ranged from zero, indicating no impairment, to 100,
indicating maximum impairment. Values above 10 reflected
an altered quality of life for that specific area (26,27). The
MRC breathlessness scale is a measurement of disability in
patients with chronic obstructive pulmonary disease. It
comprises five statements that describe nearly the entire
range of respiratory disability from none (Grade 1) to almost
complete incapacity (Grade 5) (28,29).
Patients were then divided into two groups based on the
severity of exercise gas exchange disability by desaturation
in the 6MWT. Group A demonstrated desaturation, and
Group B had no desaturation. Desaturation was defined as a
fall.4% of the resting SpO2 value (30). We chose the 6MWT
because it is a simple, efficient and low-cost tool used to
evaluate the performance of individuals during submaximal
exercise and can be even more sensitive than maximal
incremental cycle testing for the detection of oxygen
desaturation (24,30).
The lung in residual paracoccidioidomycosis
Costa AN et al.
CLINICS 2013;68(4):441-448
442
Statistical analysis was performed with GraphPad Prism
Version 5.0 for Windows (GraphPad Software, San Diego
CA, USA). Parametric variables are expressed as the mean
and standard deviation (SD), and nonparametric variables
are expressed as the median and interquartile range (IQ).
Correlations were performed using either Pearson or
Spearman tests, depending on the distribution of the
variables. Comparisons between groups were performed
with a Student’s T test or Mann-Whitney test when
appropriate. A chi-squared analysis was used to examine
categorical variables, and a Fisher exact test was used for
small samples. Statistical significance was assumed for p-
values,0.05.
Ethics Statement
Our research was approved by our two Ethics
Committees, Comissa˜o de Pesquisa do Departamento de
Cardiopneumologia and Comissa˜o de E´tica para a Ana´lise
de Projetos de Pesquisa – CAPPesq da Diretoria Clı´nica do
Hospital das Clı´nicas da Faculdade de Medicina da
Universidade de Sa˜o Paulo, on June 09, 2007, under
approval number 870/06. All patients in our study signed
an informed consent form, and all clinical investigations
were conducted in accordance with the principles expressed
in the Declaration of Helsinki.
& RESULTS
The clinical and epidemiological data for the patients and
their serum titers on CIE at the time of diagnosis and the
time of our evaluation are shown in Table 1. All but one of
the patients were smokers. The antifungal drugs used by the
patients were itraconazole (26%), sulfamethoxazole-tri-
methoprim (16%), sulfadiazine (12%) and ketoconazole
(8%). The remaining 38% used two or more of these drugs
for treatment. Patients were not HIV co-infected and had no
autoimmune disease or referred use of immunosuppressant
drugs.
Twenty-seven patients remained on antifungal medica-
tions because it is a common practice in the infectious
diseases outpatient unit to use low-dose sulfamethoxazole-
trimetropin as a maintenance treatment to prevent relapses
of the chronic forms of infections. These patients repre-
sented 40% in Group A (desaturation in 6 MWT) and 60% in
Group B (p= 0.34).
The serum CIE titer at diagnosis was significantly higher
in Group A compared with the patients without exercise
desaturation in Group B. The other clinical and epidemio-
logical parameters were not different between these two
groups.
Radiological Findings
Abnormal pulmonary findings on HRCT were observed
in all but one patient, and multiple abnormalities were often
present simultaneously (median of eight abnormalities/
patient). CT findings included architectural distortion (90%,
n = 45), interlobular septal thickening and reticulate (88%,
n = 44), centrilobular or paraseptal emphysema (82%,
n = 41), bronchial thickening (82%, n = 41), parenchymal
bands (74%, n = 37), areas of cicatricial emphysema (66%,
n = 33), nodules ,3 cm (62%, n = 31) and ground glass
opacities (46%, n = 23). Pleural thickening was observed in
10 (20%) patients, and mediastinal lymphadenopathy in
only three cases. Thirty-eight patients presented with
mosaic perfusion patterns with expiratory maneuvers. The
major tomographic findings were predominantly diffuse in
their distribution (84%), were most prominent in the
superior and medium zones and had a combination of
central and peripheral locations in 80% of cases. When
predominance was apparent, these findings were most
common in the upper and middle lung zones. The most
frequent abnormalities are shown in Figure 1 (A-F).
Notably, a comparison between Group A and B revealed
no difference in the number of interstitial fibrotic CT
abnormalities, which were architectural distortion, inter-
lobular septal thickening and reticulate and parenchymal
bands. However, when emphysema quantification scores
were compared, they were higher (more prominent emphy-
sema) in Group A than Group B (Figure 2, p = 0.0009).
Pulmonary function tests (PFT)
Lung function test results are shown in Table 2. Seven
patients (14%) presented with normal PFT. An obstructive
defect, defined as FEV1/FVC,0.70, was observed in 70%
(35) of patients (31). Of the latter, 85% (n = 30) presented
with only a mild obstruction (FEV1.60%), and only one
patient presented with a severe obstruction (FEV1,40%).
The residual volume/total lung capacity was slightly
increased, suggesting air trapping without pulmonary
hyperinflation. Only one patient presented with a pure
Table 1 - Clinical and epidemiological data of Group A (desaturation .4% in 6MWT) and Group B (desaturation ,4% in
6MWT).
n=50 GROUP A n=18 GROUP B n=32 p (A6B)
Age in years 56.9¡9.7 59.1¡2.2 55.6¡1.7 0.21
Gender male (%) 92% 89% 94% 0.62
Body mass index 24.0¡4.8 24.7¡1.4 23.6¡0.6 0.50
Tobacco exposure (%) 98% 100% 97% 1.00
Tobacco exposure in pack -
years
35(27-50) 30(20-42) 37(30-53) 0.25
Length of treatment in months 42¡34 38.2¡37.2 44¡31.7 0.56
Time between onset of
treatment and evaluation
(years)
5.9¡3.8 5.9¡3.8 5.9¡3.9 0.99
Initial CIE 1:64 (1:16-1:256) 1:128 (1:32-1:256) 1:32 (1:8-1:128) 0.01
CIE at evaluation 1:2(0-1:4) 1:2(0-1:5) 1:1.5(1-1:4) 0.62
The data are reported as either the median values (IQ) or as the mean¡SD. IQ = interquartile, SD = standard deviation,
CIE = counterimmunoelectrophoresis.
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restrictive pattern, showing a TLC of 61% of the predicted
value. Diffusing capacity was impaired in 43 (86%) patients
(mean DLCO: 60.6% of the predicted value). Nine patients
presented with a severe (DLCO,40%), 15 with a moderate
(40%,DLCO,60%) and 19 with a mild reduction
(DLCO.60%) in diffusion capacity. There was no bronch-
odilator response (data not shown). A comparison between
groups showed that Group A had significantly reduced gas
exchange and ventilatory strength than Group B (Table 2).
Exercise evaluation
The maximal exercise performance was preserved in the
PCM patients, with a VO2max value of 80.8%¡18.5 of the
predicted value. At exercise cessation, there was a large
Figure 1 - The patterns of pulmonary alterations found on HRCT. (A) Upper lobes showing septal thickening and peripheral reticulate.
(B) Upper lobes showing architectural distortion. (C) Lower lobes showing parenchymal bands. (D) Lower lobes showing non-calcified
nodules in the left lower lobe. (E) Upper lobes showing centrilobular and paraseptal emphysema. (F) Lower lobes showing
peribronchovascular thickening.
Figure 2 - Figure showing that emphysema quantification by CT
was significantly higher in the most severely impaired PCM
patients compared to the least severely impaired PCM patients.
Table 2 - Lung function measurements of Group A (desa-
turation.4% in 6 MWT) and Group B (desaturation,4%
in 6MWT).
n=50 Group A Group B
p-
value
FVC (L) 4.00¡0.82 3.75¡0.2 4.13¡0.1 0.14
% predicted 94.8¡12.1 91.0¡3.2 97.0¡1.8 0.12
FEV1 (L) 2.60¡0.68 2.38¡0.1 2.72¡0.1 0.09
% predicted 77.6¡17.0 72.1¡3.9 80.2¡2.9 0.10
FEV1/FVC 0.65¡0.11 63.3¡2.8 66.16¡1.7 0.39
% predicted 81.7¡13.4 79.3¡3.5 83.0¡2.1 0.17
FEF 25-75% (L/s) 1.6¡0.93 1.42¡0.2 1.73¡0.1 0.26
% predicted 52.1¡28.4 45.9¡6.2 55.5¡5.1 0.24
TLC (L) 6.80¡0.20 6.14¡0.3 6.47¡0.1 0.40
% predicted 100.4¡12.9 98.8¡3.9 101.3¡1.9 0.58
RV (L) 2.40¡0.73 2.41¡0.2 2.39¡0.1 0.95
% predicted 121.2¡34.5 122.4¡9.9 120.6¡5.6 0.87
RV/TLC 0.38¡0.07 0.38¡0.02 0.37¡0.01 0.58
% predicted 117.2¡23.4 120.5¡7 115.2¡3 0.51
DLCO (mL/min/mmHg) 20.4¡6.6 16.7¡1.3 22.5¡1.10 0.002
% predicted 60.6¡19.9 49.2¡3.8 66.9¡3.4 0.001
MVV (L) 98.7¡29 86.5¡20.5 105.8¡4.7 0.14
% predicted 72.5¡20.2 65.2¡3.9 76.5¡3.9 0.04
The data are reported as the means¡SD. SD = standard deviation,
FVC = forced vital capacity, FEV1 = forced expiratory volume in 1 s, FEF25-
75% = forced expiratory flow from 25 to 75% of the FVC, TLC = total lung
capacity, RV = residual volume, DLCO = carbon monoxide diffusing
capacity, MVV = maximal voluntary ventilation.
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ventilatory reserve that was accomplished without oxygen
desaturation, showing a preserved performance of the
respiratory system under effort. Cardiac behavior was
characterized by a normal oxygen pulse (VO2/HR =
11.0¡2.8 mL.min-1), and the significant cardiac reserve
suggested that there were no cardiac limitations. Of the 50
patients, only one had ECG abnormalities that were
compatible with coronary disease, which was not confirmed
by an invasive posterior coronary study. When Groups A and
B were examined, no significant difference was found
between the patients for either VO2max or oxygen pulse;
however, Group A had a lower ventilatory reserve with
higher hyperventilation (augmented VE/VCO2). In sum-
mary, Group A presented with more serious respiratory
impairments during exercise compared with Group B
(Table 3).
In the 6MWT, patients achieved a normal distance with a
median of 492 meters, which was 131% of the predicted
value, without desaturation. The distance achieved was
similar between groups. However, for the submaximal test
(very large cardiac reserve at exercise cessation), 18 (36%) of
the patients presented with a decrease .4% in SpO2, which
was indicative of an abnormal arterial-alveolar gradient that
was previously shown for PCM in other studies (32,33)
(Table 3).
Health-related quality of life (HRQOL)
The Saint George Respiratory Questionnaire scores are
presented in Table 4. Patients presented with high (worse)
scores in the symptoms and activity scales but low overall
impairments in health-related quality of life. For the MRC
Dyspnea Questionnaire, the patients had a mean value of 1,
which corresponds with ‘‘not troubled by breathlessness
except on strenuous exercise’’ (28). Even in Group A, the
more severe impairments did not translate into a worse
quality of life, as measured by either the SGRQ or MRC
Dyspnea Questionnaire. There was a strong correlation
between the two scores, with p,0.0001 and r = 0.65.
Correlation studies
The initial CIE titers inversely correlated with the DLCO
(p= 0.001, r = -0.44) and positively correlated with impairments
the in HRQOL (p= 0.021, r = 0.33). However, there was no
correlation between the CIE and any of the other parameters
analyzed in the population under study.
& DISCUSSION
In contrast with previous investigations of treated PCM
patients, we found a consistently higher incidence of
radiological involvement, with 98% of patients presenting
with at least one CT abnormality. The most common
abnormalities were architectural distortion and interlobular
septal thickening and reticulate, which were most likely
related to dissemination of the fungi through the lymphatics
and subsequent fibrosis formation (13). The finding of
peribronchovascular interstitial thickening diffusely distrib-
uted throughout the pulmonary zones in 62% of the patients
is another abnormality related to the pattern of fungal
dissemination previously described in histopathology stu-
dies (2). In contrast, centrilobular and paraseptal emphy-
sema were observed in 82% of individuals, which reflects
the high tobacco exposure in our population, a feature
regularly described in cohorts of chronic PCM (8). Finally,
different from the pre-treatment CT scan findings (2,18,34),
consolidation and cavitations were very rare, and no
reversed halo sign was observed, confirming the inactivity
of the mycosis.
Table 3 - Maximal cardiopulmonary and 6MWT tests for Group A (desaturation .4% in 6MWT) and Group B
(desaturation ,4% in 6MWT).
n=50 Group A Group B
Cardiopulmonary test p-value
VO2 max (% predicted) 80.8¡18.5 79.5¡3.9 81.6¡3.6 0.70
RER 1.18 (1.12-1.26) 1.18 (1.12-1.24) 1.18 (1.11-1.27) 0.89
Ventilatory reserve (%) 40.4¡17 21.2¡5.2 39.4¡4.3 0.01
VE/VCO2 36.0¡8 38.3¡1.5 34.2¡1.2 0.04
VO2/HR (mL.min
-1) 11.0¡2.8 10.0¡0.7 11.3¡0.4 0.13
HR (% predicted) 82.4¡13 86.9¡2.5 80.3¡2.4 0.07
SpO2
N Initial 97 (96-98) 96.2¡0.36 97.0¡0.3 0.11
N Final 94 (92-96) 91.7¡1 94.7¡0.4 0.04
6MWT p-value
Walked distance (meters) 492 (456-520) 431 (354-480) 477 (306-492) 0.71
SpO2
N Initial 96¡1.6 95.9¡0.3 95.9¡0.28 l 0.96
N Final 93¡4 89.1¡1.0 94.8¡0.3 ,0.0001
HR (% predicted) 62.8¡15 69.8¡2.1 63.0¡1.3 0.01
The data are reported as either the median values (IQ) or the means¡SD. IQ = interquartile, ST = standard deviation, VO2 max = maximal oxygen
consumption, VE/VCO2 = ventilatory equivalent ratio for carbon dioxide, VO2/FC = oxygen pulse, HR = heart rate, SpO2 = peripheral oxygen saturation.
Table 4 - Saint George Respiratory Questionnaire scores
for Group A (desaturation .4% in 6 MWT) and Group B
(desaturation ,4% in 6MWT).
Symptoms n=50 Group A Group B p (A6B)
% total (IQ) 17.8 (3.7-34.9) 18.2 (6-36) 16.9 (0.5-34.4) 0.61
Activity
% total (IQ) 29.5 (5.8-41.8) 26.4 (0-41.8) 29.5 (6.0-41.8) 0.76
Impacts
% total (IQ) 3.2 (0-12.9) 3.5 (0-12.9) 3.1 (0-14.5) 1.00
Overall ¡ SD
% total¡ST 16.2¡13.8 24.7¡10.4 14.5¡13.9 0.9
The data are reported as either the median values (IQ) or the means¡SD.
IQ = interquartile, ST standard deviation.
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It has been shown by thoracic roentgenogram that
fungus-induced lung fibrosis in the form of residual
lesions occurs in up to 53% of treated patients (15), which
has led to experimental studies involving pentoxifylline as
a complementary treatment for pulmonary PCM due to its
immunomodulatory and anti-fibrotic properties (35).
However, this radiologic approach may not be beneficial
for an even greater proportion of individuals with
interstitial pulmonary abnormalities because thoracic
roentgenogram is not sufficiently sensitive to evaluate
these lesions. In addition, chest X-rays are not sufficiently
sensitive to confirm the possible presence of lung
emphysema (15). Indeed, HRCT is currently the standard
approach to confirm lung parenchymal involvement
(18,36,37). As expected, using HRCT, we found a greater
proportion of lung residual abnormalities than previously
reported, confirming that PCM can lead to even further
radiological involvement of respiratory tissue than pre-
viously thought.
Despite these findings, the pulmonary functional
impairments were not that limiting. On average, the
patients presented with a mild obstructive disorder
associated with a mild reduction in diffusion capacity
and slight reduction in the maximal voluntary ventilation.
Indeed, most of the patients were classified as having
mild obstructive defects, and only one patient presented
with severe obstruction. This contrasts with earlier studies
in which more than 50% of the patients evaluated
presented with a moderate to severe obstructive defect
(38), the alveolar-arterial gradient was altered in all
patients (39,40), and cor pulmonale was present in almost
25% of the cases (40). This discrepancy may be related to
the more restricted access to health care facilities in Brazil
at the time these studies were conducted, which delayed
proper diagnosis and treatment. In contrast, in our
patients, the DLCO was severely impaired in only 18%
of patients. A plausible explanation for these functional
findings of mild obstruction with more severe DLCO
impairment is the presence of interstitial fibrotic disease
associated with pulmonary emphysema, as described for
Combined Pulmonary Fibrosis and Emphysema (CPFE).
In this condition, there are subnormal spirometry exams,
despite severe impairment in DLCO, that are most likely
secondary to overinflation and an increase in pulmonary
compliance due to the loss of elasticity in areas with
emphysema that are balanced by the loss of volume and
decreased compliance caused by fibrosis (41).
When our patients performed maximal and submaximal
exercises, their performances were normal. Furthermore, we
could not find any ventilatory or cardiac limitations. This
behavior was also reflected in the quality of life measure-
ments. On average, the patients presented with low quality
of life impairments, as measured by the Saint George
Respiratory Questionnaire. The mean score of 16 can be
interpreted as altered because it is higher than 10 (29), but
compared with the general population, it remained within
the 80th percentile limit (26), indicating that the HRQOL was
not impaired in a severe manner. Indeed, in the MRC
questionnaire, the patients had a mean value of 1.
There was, however, a substantial percentage (36%) of
patients who presented with significant gas exchange
dysfunction that was confirmed by desaturation (decrease
$4%) in the 6MWT. This proportion of impaired patients is
smaller than previously thought, but this finding suggests
that a proportion of PCM patients will present with some
degree of respiratory distress during exercise. Notably, both
groups had comparable interstitial fibrotic alterations
regarding lung CTs, type and length of treatments, age
and tobacco exposure. Patients with exercise desaturation
(Group A) presented with more severe emphysema than
Group B, even though they had similar tobacco exposure.
One likely explanation for this finding is the higher pre-
treatment serology titers in Group B, denoting a putative
higher fungal burden and subsequently stronger inflamma-
tory response. In fact, the initial serology was inversely
correlated with the DLCO and positively correlated with
impairment in the health-related quality of life question-
naire. This aspect warrants further evaluation.
It is also conceivable that in some patients, the diagnosis
was delayed; therefore, at the time treatment began, the
fibrosis was already at an advanced stage. Similarly,
differences in the host-parasite relationship due to distinct
host immune responses and regulation among the patients
could also explain the different outcomes (42,43). Finally,
genetic differences in the response to tobacco exposure
leading to more severe emphysema in face of comparable
tobacco exposure could explain why a subgroup of patients
developed higher levels of emphysema (44). Also, the
influence of genetic background on emphysema severity
could have been accentuated by the concomitant pulmonary
insult caused by the fungi. This is of particular interest
because emphysema was the major tomographic finding
associated with more intense impairments in aerobic
capacity and gas exchange.
Our study has several limitations. We could not assess the
patients at the onset of antifungal therapy, and information
regarding the clinical course of the disease was retro-
spectively assessed. Notably, these data are particularly
difficult to interpret because the CF of the mycosis has a
very insidious and often subclinical course, and at the time
of diagnosis, the patients usually exhibit marked clinical-
radiological dissociation (4). Tobacco exposure may indeed
be a confounding variable. However, obtaining a group of
patients without tobacco exposure is not feasible when
studying the chronic form of PCM because a smoking habit
is almost universal in individuals with this form of mycosis
(2,8,45). Additionally, patients used different classes of
drugs for treatment, which can be a confounding factor for
the final endpoints, but currently, there are no studies
demonstrating the improved efficacy of one antifungal drug
compared with others (9,10,46,47).
In conclusion, we showed that patients with the chronic
form of PCM and high exposure to tobacco displayed
several residual lesions on the lung CT scans in association
with emphysema. However, these residual lesions did not
predict severe pulmonary functional impairments or a
decreased HRQOL. A subset of patients, however, persisted
with gas exchange impairments during exercise and higher
respiratory distress and should be identified by the simple
and inexpensive 6MWT. The main factors involved with the
respiratory impairments were emphysema, as shown by the
HRCT scan, and higher initial serology titer, as shown by
the CIE and higher initial serology titer. This stresses the
value of adequate and early specific treatments associated
with tobacco cessation. The factors involved in this more
severe evolution of PCM, however, remain unclear and
require further investigation.
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